Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder

Gencer, Özlem; Emiroglu, Fatma Neslihan Inal; Miral, Süha; Baykara, Burak; Baykara, A; Dırık, Eray

doi:10.1007/s00787-007-0656-6

Cited by 46 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risperidone is indicated for acute and chronic schizophrenic psychoses and other psychotic conditions with positive and negative symptoms. It is also indicated for affective symptoms associated with schizophrenia (1–6,10–39), and it has been shown that the severity of psychotic symptoms may be associated with reduced heart rate variability (40). Moreover, paliperidone (the principal active metabolite of risperidone) has been shown to be effective, at low doses, in reducing behavioural disturbances and symptoms in patients with delirium (41).…”

Section: Discussionmentioning

confidence: 99%

Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature

Gallerani¹,

Imberti²,

Mari³

et al. 2012

Acta Neuropsychiatr.

View full text Add to dashboard Cite

pulmonary embolism: a harmful association? Case series and review of the literature.Objective: Risperidone is an atypical antipsychotic drug used to treat a number of psychiatric diseases, such as schizophrenia, schizoaffective and bipolar disorders and irritability in children with autism. Moreover, it is also often administered for short-term treatment of persistent aggression in people with moderate-to-severe Alzheimer's dementia. A possible association between risperidone and venous thromboembolism (VTE) has been described. We intended to verify the dimension of the problem in our hospital setting. Methods: We considered all consecutive patients hospitalised in our Internal Medicine Department from January 2004 to December 2010, who were treated with risperidone and presented pulmonary embolism (PE). Results: Four cases of patients, apparently free from the well-known major risk factors for VTE (i.e. cancer, prolonged immobilisation, acute cardiac and respiratory failure, infections), who presented PE associated with risperidone therapy, were reported in details. Significant OutcomesOur study showed:• Pulmonary embolism is not a negligible finding in a cohort of patients admitted to a medical department (0.66%). • A possible association between risperidone and pulmonary embolism has been shown (26/494), especially in elderly patients. • Four patients, apparently free from all the major risk factors, developed a pulmonary embolism, although they had all a favourable outcome. Limitations• As a result of a small series of clinical cases, any definite conclusion cannot be drawn. Further investigation on larger scale cohorts of patients will be needed to confirm this possible, and potentially harmful, association.

show abstract

Section: Discussionmentioning

confidence: 99%

Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature

Gallerani¹,

Imberti²,

Mari³

et al. 2012

Acta Neuropsychiatr.

View full text Add to dashboard Cite

show abstract

“…In an open-label continuation study following a randomised, double-blind, controlled trial of risperidone and haloperidol for 12 weeks in autistic children and adolescents, it was found that risperidone is more effective and better tolerated than haloperidol. The study also showed that autistic children treated with risperidone do not have the same language deterioration as those treated with haloperidol 23. In a randomised, double-blind, crossover study of 19 children and adolescents aged 7–17 years with Tourette disorder treated with risperidone or pimozide, risperidone was found to be superior to pimozide but was associated with greater weight gain 24.…”

Section: Are Atypical Antipsychotics Better Than Typical Antipsychotics?mentioning

confidence: 93%

Review on the current use of antipsychotic drugs in children and adolescents

Almandil

Wong²

2011

Archives of Disease in Childhood - Education and Practice

View full text Add to dashboard Cite

Antipsychotic (neuroleptic) drugs are used in the treatment of various psychiatric disorders in children and adolescents. There is a lack of information about the efficacy and safety of antipsychotics in young people. Much of the information available is extrapolated from adult studies; in particular, little is known about the long-term effects of these drugs on the development of the central nervous system. Over the last two decades, typical antipsychotics have largely been replaced by atypical antipsychotics. With this increase in use of atypical antipsychotic drugs, there has been growing concern about the appropriate use of these drugs and the fact that they appear to be associated with metabolic abnormalities such as weight gain, diabetes and related cardiovascular effects. This paper provides a review of current practice and evidence based use of antipsychotic drugs in children.

show abstract

“…Drowsiness and weight gain were the most commonly reported side effects. Most of seven randomized clinical trials with risperidone, two re-analyses and two association studies demonstrated some efficacy regarding analyzed parameters (irritability, aggressiveness, hyperactivity, general functioning) [73][74][75][76][77][78][79][80][81] with risperidone. Effective doses were low, averaging 2 mg per day.…”

Section: Aggressive Behavior and Irritabilitymentioning

confidence: 99%

Autism spectrum disorders: an overview on diagnosis and treatment

Brentani

Paula

Bordini

et al. 2013

Rev. Bras. Psiquiatr.

112

View full text Add to dashboard Cite

Pervasive developmental disorders are now commonly referred to as autism spectrum disorders (ASDs). ASDs present with a range of severity and impairments, and often are a cause of severe disability, representing a major public health concern. The diagnostic criteria require delays or abnormal functioning in social interaction, language, and/or imaginative play within the first 3 years of life, resulting in a deviation from the developmental pattern expected for the age. Because establishing a diagnosis of ASD is possible as early as 18-24 months of age, clinicians should strive to identify and begin intervention in children with ASD as soon as signs are manifest. Increasing efforts are underway to make ASD screening universal in pediatric healthcare. Given the crucial importance of early identification and multiple modalities of treatment for ASD, this review will summarize the diagnostic criteria, key areas for assessment by clinicians, specific scales and instruments for assessment, and discussion of evidence-based treatment programs and the role of specific drug therapies for symptom management.

show abstract

Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder

Abstract: These results demonstrate that risperidone is more efficacious and well tolerated than haloperidol in the long-term maintenance treatment of autistic disorder.

Cited by 46 publications

References 27 publications

Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature

Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature

Review on the current use of antipsychotic drugs in children and adolescents

Autism spectrum disorders: an overview on diagnosis and treatment

Contact Info

Product

Resources

About